🔗 Share this article

Given that the United States undertakes sweeping changes to its vaccine schedules, one figure has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations in the global health crisis and has zeroed in on alleged deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Schedule

Health officials were set to unveil radical changes to the childhood immunization program in December, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would put the US at odds with a large portion of the world with insufficient data for benefit. The announcement has been pushed back until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon rolling back already-approved immunizations at the FDA.

The new acting director has repeatedly called for halting certain childhood immunization guidelines in the US to become more in line with Denmark, a nation with nationalized medicine and a population approximately the size of the state of Wisconsin.

In her initial comments, she has continued to focus on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Expertise

The appointee has no apparent track record in drug development, oversight or leadership, which has been customary for previous leaders of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the necessary background” for overseeing the CDER, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a major agency. She has no expertise in drug approvals.”

Former commissioners of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who headed CBER have had.”

This division has an immense range of responsibilities at the agency, Woodcock pointed out.

“Everybody just focuses on the new drug program, but the generic drug division approves numerous generic medications. There is also a biosimilars program, over-the-counter program and so forth, and each of these need to be looked after,” she explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial administrative component to the position, which oversees over 5,000 employees. “It’s a huge management job, if you do it right,” the former official concluded.

Response and Disputed Policies

In response to concerns about Høeg’s qualifications and whether this appointment indicates more teamwork among regulatory chiefs on vaccines, a spokesperson stated that the “concerns are based on flawed premises”.

“This background is consistent with the duties of her role,” the representative said, noting the months Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious one-day therapy clearance system that apparently concerned her preceding directors. “By what process are these drugs being chosen for this voucher program? Who is making the choices?” Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he stated, “the FDA appears to be shifting towards less stringent rules of most medications, with the exception of immunizations.”

Documented History on Immunizations

Regarding immunizations, Høeg has a more established, if concerning, track record, critics said. She published a analysis using unverified crowd-sourced reports to assess the frequency of heart inflammation after COVID-19 immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the current government included altering regulations for recently developed shots and ending “unnecessary” immunizations, she remarked post-election on a online show. At the agency, Høeg has reportedly floated the idea of barring young men from receiving COVID-19 vaccinations.

“She’s an thorough dogmatist who starts off with her conclusions and tailors the evidence to accommodate the science in a very disingenuous, dishonest way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with other dissenters, {like|